(Q34484837)

2 August 2017

title

Prophylactic cranial irradiation revisited: cost-effectiveness and quality of life in small-cell lung cancer (English)

1 reference

cost-effectiveness analysis

2 August 2017

1 reference

1 reference

T H Patricia Tai

1

1 reference

2 August 2017

Edward Yu

2

1 reference

2 August 2017

Peter Dickof

3

1 reference

2 August 2017

Glen Beck

4

1 reference

2 August 2017

Jon Tonita

5

1 reference

2 August 2017

Tete Ago

6

1 reference

2 August 2017

David Skarsgard

7

1 reference

2 August 2017

Marlene Schmidt

8

1 reference

2 August 2017

Matthew Schmid

9

1 reference

2 August 2017

John S K Liem

10

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

International Journal of Radiation Oncology Biology Physics

2 August 2017

published in

1 reference

2 August 2017

volume

52

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

68-74

1 reference

Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer. Potential benefit restricted to patients with complete response

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Prophylactic cranial irradiation in small cell lung cancer (SCLC) makes a comeback

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Prophylactic cranial irradiation in limited stage small cell lung cancer: Survival benefit in patients with favourable characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Prophylactic Cranial Irradiation for Patients With Small-Cell Lung Cancer in Complete Remission

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Comparative study of prophylactic cranial irradiation in patients with small cell lung cancer achieving a complete response: a long-term follow-up result

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Treatment of small cell lung cancer. Two-drug versus four-drug chemotherapy and loco-regional irradiation with or without prophylactic cranial irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Comparison of symptomatic and prophylactic irradiation of brain metastases from oat cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Is prophylactic cranial irradiation indicated in small-cell lung cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Economic evaluation of trends in cancer therapy. Marginal or average costs?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Diagnostic and therapeutic approaches to lung cancer in Canada and their costs

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Economic analyses in health care: an introduction to the methodology with an emphasis on radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

The Markov process in medical prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Markov models in medical decision making: a practical guide.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. The AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Economic evaluation of cancer treatments: a review of the methods

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Some guidelines on the use of cost effectiveness league tables

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Efficacy and safety of prophylactic cranial irradiation in patients with small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901748-5

7 January 2021

10.1016/S0360-3016(01)01748-5

Identifiers

DOI

1 reference

2 August 2017

1 reference